Molecular diagnosis of primary hyperparathyroidism in familial cancer syndromes

Bibliography

• ADAMI S, MARCOCCI C, GATTI D: Epidemiology of primary hyperparathyroidism in Europe. J. Bone Miner. Res. (2002) 17(Suppl. 2):N18-N23.
   PubMed Web of Science ®Google Scholar
• ANDERSSON P, RYDBERG E, WILLENHEIMER R: Primary hyperparathyroidism and heart disease – a review. Eur. Heart J. (2004) 25(20):1776-1787.
   PubMed Web of Science ®Google Scholar
• MARX SJ: Hyperparathyroid and hypoparathyroid disorders. N. Engl. J. Med. (2000) 343(25):1863-1875.
   PubMed Web of Science ®Google Scholar
• CARLING T: Molecular pathology of parathyroid tumours. Trends Endocrinol. Metab. (2001) 12(2):53-58.
   PubMed Web of Science ®Google Scholar
• LAL G, CLARK OH: Primary hyperparathyroidism: controversies in surgical management. Trends Endocrinol. Metab. (2003) 14(9):417-422.
   PubMed Web of Science ®Google Scholar
• CARLING T, UDELSMAN R: Parathyroid surgery in familial hyperparathyroid disorders. J. Intern. Med. (2005) 257(1):27-37.
   PubMed Web of Science ®Google Scholar
• MARX SJ, SIMONDS WF, AGARWAL SK et al.: Hyperparathyroidism in hereditary syndromes: special expressions and special managements. J. Bone Miner. Res. (2002) 17(Suppl. 2):N37-N43.
   PubMed Web of Science ®Google Scholar
• BRANDI ML, GAGEL RF, ANGELI A et al.: Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab. (2001) 86(12):5658-5671.
   PubMed Web of Science ®Google Scholar
• GIMM O: Multiple endocrine neoplasia type 2: clinical aspects. In: Genetic Disorders of Endocrine Neoplasia. Dahia PLM, Eng C (Ed), Karger, Basel (2001):103-130.
   Google Scholar
• AGHA A, CARPENTER R, BHATTACHARYA S et al.: Parathyroid carcinoma in multiple endocrine neoplasia type 1 (MEN1) syndrome: two case reports of an unrecognised entity. J. Endocrinol. Invest. (2007) 30(2):145-149.
   PubMed Web of Science ®Google Scholar
• DIONISI S, MINISOLA S, PEPE J et al.: Concurrent parathyroid adenomas and carcinoma in the setting of multiple endocrine neoplasia type 1: presentation as hypercalcemic crisis. Mayo Clin. Proc. (2002) 77(8):866-869.
   PubMed Web of Science ®Google Scholar
• JENKINS PJ, SATTA MA, SIMMGEN M et al.: Metastatic parathyroid carcinoma in the MEN2A syndrome. Clin. Endocrinol. (Oxford) (1997) 47(6):747-751.
   PubMed Web of Science ®Google Scholar
• SATO M, MIYAUCHI A, NAMIHIRA H et al.: A newly recognized germline mutation of MEN1 gene identified in a patient with parathyroid adenoma and carcinoma. Endocrine (2000) 12(3):223-226.
   PubMed Web of Science ®Google Scholar
• CHEN JD, MORRISON C, ZHANG C et al.: Hyperparathyroidism-jaw tumour syndrome. J. Int. Med. (2003) 253:634-642.
   PubMed Web of Science ®Google Scholar
• RAUE F, HAAG C, SCHULZE E, FRANK-RAUE K: The role of the extracellular calcium-sensing receptor in health and disease. Exp. Clin. Endocrinol. Diabetes (2006) 114(8):397-405.
   PubMed Web of Science ®Google Scholar
• GUNN IR, GAFFNEY D: Clinical and laboratory features of calcium-sensing receptor disorders: a systematic review. Ann. Clin. Biochem. (2004) 41(Part 6):441-458.
   PubMed Web of Science ®Google Scholar
• MOLOGNI L, SALA E, CAZZANIGA S et al.: Inhibition of RET tyrosine kinase by SU5416. J. Mol. Endocrinol. (2006) 37(2):199-212.
   PubMed Web of Science ®Google Scholar
• MARX SJ: Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat. Rev. Cancer (2005) 5(5):367-375.
   PubMed Web of Science ®Google Scholar
• MULLIGAN LM, KWOK JB, HEALEY CS et al.: Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature (1993) 363:458-460.
   PubMed Web of Science ®Google Scholar
• LEMMENS I, VAN DE VEN WJ, KAS K et al.: Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European consortium on MEN1. Hum. Mol. Genet. (1997) 6(7):1177-1183.
   PubMed Web of Science ®Google Scholar
• CHANDRASEKHARAPPA SC, GURU SC, MANICKAM P et al.: Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science (1997) 276(5311):404-407.
   PubMed Web of Science ®Google Scholar
• CETANI F, PARDI E, AMBROGINI E et al.: Genetic analyses in familial isolated hyperparathyroidism: implication for clinical assessment and surgical management. Clin. Endocrinol. (Oxford) (2006) 64(2):146-152.
   PubMed Web of Science ®Google Scholar
• HAVEN CJ, VAN PUIJENBROEK M, TAN MH et al.: Identification of MEN1 and HRPT2 somatic mutations in paraffin-embedded (sporadic) parathyroid carcinomas. Clin. Endocrinol. (Oxford) (2007) 67(3):370-376.
   PubMed Web of Science ®Google Scholar
• BURGESS JR, DAVID R, GREENAWAY TM, PARAMESWARAN V, SHEPHERD JJ: Osteoporosis in multiple endocrine neoplasia type 1: severity, clinical significance, relationship to primary hyperparathyroidism, and response to parathyroidectomy. Arch. Surg. (1999) 134(10):1119-1123.
   PubMed Web of Science ®Google Scholar
• HEBERT SC: Therapeutic use of calcimimetics. Annu. Rev. Med. (2006) 57:349-364.
   PubMed Web of Science ®Google Scholar
• VILLABLANCA A, HOOG A, LARSSON C, TEH B, TEAN: Molecular genetics of familial hyperparathyroidism. J. Endocr. Genet. (2001) 2:3-12.
   Google Scholar
• SCHUSSHEIM DH, SKARULIS MC, AGARWAL SK et al.: Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends Endocrinol. Metab. (2001) 12(4):173-178.
   PubMed Web of Science ®Google Scholar
• DOHERTY GM, OLSON JA, FRISELLA MM et al.: Lethality of multiple endocrine neoplasia type 1. World J. Surg. (1998) 22(6):581-587.
   PubMed Web of Science ®Google Scholar
• CHANDRASEKHARAPPA SC, TEH BT: Functional studies of the MEN1 gene. J. Intern. Med. (2003) 253(6):606-615.
   PubMed Web of Science ®Google Scholar
• GURU SC, GOLDSMITH PK, BURNS AL et al.: Menin, the product of the MEN1 gene, is a nuclear protein. Proc. Natl. Acad. Sci. USA (1998) 95:1630-1634.
   PubMed Web of Science ®Google Scholar
• AGARWAL SK, KENNEDY PA, SCACHERI PC et al.: Menin molecular interactions: insights into normal functions and tumorigenesis. Horm. Metab. Res. (2005) 37(6):369-374.
   PubMed Web of Science ®Google Scholar
• MARSH DJ, ZORI RT: Genetic insights into familial cancers – update and recent discoveries. Cancer Lett. (2002) 181:125-164.
   PubMed Web of Science ®Google Scholar
• BALOGH K, RACZ K, PATOCS A, HUNYADY L: Menin and its interacting proteins: elucidation of menin function. Trends Endocrinol. Metab. (2006) 17(9):357-364.
   PubMed Web of Science ®Google Scholar
• HUGHES CM, ROZENBLATT-ROSEN O, MILNE TA et al.: Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol. Cell (2004) 13(4):587-597.
   PubMed Web of Science ®Google Scholar
• SOWA H, KAJI H, KITAZAWA R et al.: Menin inactivation leads to loss of transforming growth factor β inhibition of parathyroid cell proliferation and parathyroid hormone secretion. Cancer Res. (2004) 64(6):2222-2228.
   PubMed Web of Science ®Google Scholar
• KAJI H, CANAFF L, LEBRUN JJ, GOLTZMAN D, HENDY GN: Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type β signaling. Proc. Natl. Acad. Sci. USA (2001) 98(7):3837-3842.
   PubMed Web of Science ®Google Scholar
• DREIJERINK KMA, HOPPENER JWM, TIMMERS HTM, LIPS CJM: Mechanisms of disease: multiple endocrine neoplasia type 1 – relation to chromatin modifications and transcription regulation. Nat. Clin. Pract. Endocrinol. Metab. (2006) 2(10):562-570.
   PubMedGoogle Scholar
• MARX SJ, AGARWAL SK, HEPPNER C et al.: The gene for multiple endocrine neoplasia type 1: recent findings. Bone (1999) 25(1):119-122.
   PubMed Web of Science ®Google Scholar
• AGARWAL SK, LEE BURNS A, SUKHODOLETS KE et al.: Molecular pathology of the MEN1 gene. Ann. NY Acad. Sci. (2004) 1014:189-198.
   PubMed Web of Science ®Google Scholar
• HOWELL VM, CARDINAL JW, RICHARDSON AL et al.: Rapid mutation screening for HRPT2 and MEN1 mutations associated with familial and sporadic primary hyperparathyroidism. J. Mol. Diagn. (2006) 8(5):559-566.
   PubMed Web of Science ®Google Scholar
• GIRAUD S, ZHANG CX, SEROVA-SINILNIKOVA O et al.: Germ-line mutation analysis in patients with multiple endocrine neoplasia type 1 and related disorders. Am. J. Hum. Genet. (1998) 63:455-467.
   PubMed Web of Science ®Google Scholar
• WAUTOT V, VERCHERAT C, LESPINASSE J et al.: Germline mutation profile of MEN1 in multiple endocrine neoplasia type 1: search for correlation between phenotype and the functional domains of the MEN1 protein. Hum. Mutat. (2002) 20(1):35-47.
   PubMed Web of Science ®Google Scholar
• GEORGITSI M, RAITILA A, KARHU A et al.: Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J. Clin. Endocrinol. Metab. (2007) 92(8):3321-3325.
   PubMed Web of Science ®Google Scholar
• PELLEGATA NS, QUINTANILLA-MARTINEZ L, SIGGELKOW H et al.: Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc. Natl. Acad. Sci. USA (2006) 103(42):15558-15563.
   PubMed Web of Science ®Google Scholar
• DWIGHT T, TWIGG S, DELBRIDGE L et al.: Loss of heterozygosity in sporadic parathyroid tumours: involvement of chromosome 1 and the MEN1 gene locus in 11q13. Clin. Endocrinol. (2000) 53:85-92.
   PubMed Web of Science ®Google Scholar
• TANAKA C, YOSHIMOTO K, YAMADA S et al.: Absence of germ-line mutations of the multiple endocrine neoplasia type 1 (MEN1) gene in familial pituitary adenoma in contrast to MEN1 in Japanese. J. Clin. Endocrinol. Metab. (1998) 83(3):960-965.
   PubMed Web of Science ®Google Scholar
• CREPIN M, ESCANDE F, PIGNY P et al.: Efficient mutation detection in MEN1 gene using a combination of single-strand conformation polymorphism (MDGA) and heteroduplex analysis. Electrophoresis (2003) 24(1-2):26-33.
   PubMed Web of Science ®Google Scholar
• CREPIN M, PIGNY P, ESCANDE F et al.: Evaluation of denaturing high performance liquid chromatography for the mutational analysis of the MEN 1 gene. J. Mol. Endocrinol. (2006) 36(2):369-376.
   PubMed Web of Science ®Google Scholar
• LAIRMORE TC, PIERSALL LD, DEBENEDETTI MK et al.: Clinical genetic testing and early surgical intervention in patients with multiple endocrine neoplasia type 1 (MEN 1). Ann. Surg. (2004) 239(5):637-645; discussion 645-637.
   PubMed Web of Science ®Google Scholar
• PONDER BA: Multiple endocrine neoplasia type 2. In: The Genetic Basis of Human Cancer. Vogelstein B, Kinzler KW (Eds), The McGraw-Hill Companies, Inc., New York, USA (1998):475-487.
   Google Scholar
• CARTER C, EASTON DF, MATHEW CG et al.: Exclusion of linkage of loci on chromosome 19 with multiple endocrine neoplasia, type 2. Cytogenet. Cell Genet. (1987) 45:33-37.
   PubMedGoogle Scholar
• PONDER BA, PONDER MA, COFFEY R et al.: Risk estimation and screening in families of patients with medullary thyroid carcinoma. Lancet (1988) 1(8582):397-401.
   PubMed Web of Science ®Google Scholar
• MARSH DJ, MULLIGAN LM, ENG C: RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. Horm. Res. (1997) 47:168-178.
   PubMed Web of Science ®Google Scholar
• POGUE-GEILE KL, CHEN R, BRONNER MP et al.: Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS Med. (2006) 3(12):E516.
   PubMed Web of Science ®Google Scholar
• FRANK-RAUE K, RONDOT S, HOEPPNER W et al.: Coincidence of multiple endocrine neoplasia types 1 and 2: mutations in the RET protooncogene and MEN1 tumor suppressor gene in a family presenting with recurrent primary hyperparathyroidism. J. Clin. Endocrinol. Metab. (2005) 90(7):4063-4067.
   PubMed Web of Science ®Google Scholar
• ENG C, SMITH DP, MULLIGAN LM et al.: Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum. Mol. Genet. (1994) 3(2):237-241.
   PubMed Web of Science ®Google Scholar
• CARLSON KM, DOU S, CHI D et al.: Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc. Natl. Acad. Sci. USA (1994) 91(4):1579-1583.
   PubMed Web of Science ®Google Scholar
• HOFSTRA RM, LANDSVATER RM, CECCHERINI I et al.: A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature (1994) 367(6461):375-376.
   PubMed Web of Science ®Google Scholar
• MULLIGAN LM, ENG C, HEALEY CS et al.: Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat. Genet. (1994) 6(1):70-74.
   PubMed Web of Science ®Google Scholar
• MYERS SM, ENG C, PONDER BA, MULLIGAN LM: Characterization of RET proto-oncogene 3′ splicing variants and polyadenylation sites: a novel C-terminus for RET. Oncogene (1995) 11:2039-2045.
   PubMed Web of Science ®Google Scholar
• AIRAKSINEN MS, SAARMA M: The GDNF family: signalling, biological functions and therapeutic value. Nat. Rev. Neurosci. (2002) 3(5):383-394.
   PubMed Web of Science ®Google Scholar
• HANSFORD J, MULLIGAN LM: Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J. Med. Genet. (2000) 37:817-827.
   PubMed Web of Science ®Google Scholar
• IVANCHUK SM, ENG C, CAVENEE WK, MULLIGAN LM: The expression of RET and its multiple splice forms in developing human kidney. Oncogene (1997) 14:1811-1818.
   PubMed Web of Science ®Google Scholar
• KOUVARAKI MA, SHAPIRO SE, PERRIER ND et al.: RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid (2005) 15(6):531-544.
   PubMed Web of Science ®Google Scholar
• DE GRAFF E, SRINIVAS S, KILKENNY C et al.: Differential activities of the RET tyrosine kinase receptor isoforms during mammalian embryogenesis. Genes Dev. (2001) 15:2433-2444.
   PubMed Web of Science ®Google Scholar
• ENG C, CLAYTON D, SCHUFFENECKER I et al.: The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. J. Am. Med. Assoc. (1996) 276:1575-1579.
   PubMed Web of Science ®Google Scholar
• KITAMURA Y, SCAVARDA N, WELLS SA Jr, JACKSON CE, GOODFELLOW PJ: Two maternally derived missense mutations in the tyrosine kinase domain of the RET protooncogene in a patient with de novo MEN 2B. Hum. Mol. Genet. (1995) 4(10):1987-1988.
   PubMed Web of Science ®Google Scholar
• MUSHOLT PB, MUSHOLT TJ, GOODFELLOW PJ et al.: “Cold” single-strand conformational variants for mutation analysis of the RET protooncogene. Surgery (1997) 122(2):363-370; discussion 370-361.
   PubMed Web of Science ®Google Scholar
• BLANK RD, SKLAR CA, MARTIN ML: Denaturing gradient gel electrophoresis to diagnose multiple endocrine neoplasia type 2. Clin. Chem. (1996) 42(4):598-603.
   PubMedGoogle Scholar
• MARSH DJ, THEODOSOPOULOS G, HOWELL V et al.: Rapid mutation scanning of genes associated with familial cancer syndromes using denaturing high-performance liquid chromatography. Neoplasia (2001) 3(3):236-244.
   PubMed Web of Science ®Google Scholar
• SCHUFFENECKER I, BILLAUD M, CALENDER A et al.: RET proto-oncogene mutations in French MEN 2A and FMTC families. Hum. Mol. Genet. (1994) 3(11):1939-1943.
   PubMed Web of Science ®Google Scholar
• SCHUFFENECKER I, VIRALLY-MONOD M, BROHET R et al.: Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D'etude des tumeurs a calcitonine. J. Clin. Endocrinol. Metab. (1998) 83(2):487-491.
   PubMed Web of Science ®Google Scholar
• ENG C, MULLIGAN LM, SMITH DP et al.: Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin. Endocrinol. (Oxford) (1995) 43(1):123-127.
   PubMed Web of Science ®Google Scholar
• LAKHANI VT, YOU YN, WELLS SA: The multiple endocrine neoplasia syndromes. Annu. Rev. Med. (2007) 58:253-265.
   PubMed Web of Science ®Google Scholar
• MARSH DJ, MCDOWALL D, HYLAND VJ et al.: The identification of false positive responses to the pentagastrin stimulation test in RET mutation negative members of MEN 2A families. Clin. Endocrinol. (Oxford) (1996) 44(2):213-220.
   PubMed Web of Science ®Google Scholar
• LEAROYD DL, MARSH DJ, RICHARDSON AL et al.: Genetic testing for familial cancer. Consequences of RET proto-oncogene mutation analysis in multiple endocrine neoplasia, type 2. Arch. Surg. (1997) 132(9):1022-1025.
   PubMed Web of Science ®Google Scholar
• GUILLEM JG, WOOD WC, MOLEY JF et al.: ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J. Clin. Oncol. (2006) 24(28):4642-4660.
   PubMed Web of Science ®Google Scholar
• CARLOMAGNO F, VITAGLIANO D, GUIDA T et al.: ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. (2002) 62(24):7284-7290.
   PubMed Web of Science ®Google Scholar
• CARLOMAGNO F, SANTORO M: Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer. J. Chemother. (2004) 16(Suppl. 4):49-51.
   PubMed Web of Science ®Google Scholar
• SIMONDS WF, JAMES-NEWTON LA, AGARWAL SK et al.: Familial isolated hyperparathyroidism: clinical and genetic characteristics of 36 kindreds. Medicine (Baltimore) (2002) 81(1):1-26.
   PubMed Web of Science ®Google Scholar
• HOWELL VM, ZORI RT, STALKER HJ et al.: A molecular diagnosis of hyperparathyroidism-jaw tumor syndrome in an adolescent with recurrent kidney stones. J. Pediatr. (2004) 145(4):567.
   PubMed Web of Science ®Google Scholar
• KELLY TG, SHATTUCK TM, REYES-MUGICA M et al.: Surveillance for early detection of aggressive parathyroid disease: carcinoma and atypical adenoma in familial isolated hyperparathyroidism associated with a germline HRPT2 mutation. J. Bone Miner. Res. (2006) 21(10):1666-1671.
   PubMed Web of Science ®Google Scholar
• YAMASHITA Y, AKIYAMA T, MIZUSAWA N, YOSHIMOTO K, GOTO M: A case of hyperparathyroidism-jaw tumour syndrome found in the treatment of an ossifying fibroma in the maxillary bone. Int. J. Oral Maxillofac. Surg. (2007) 36(4):365-369.
   PubMed Web of Science ®Google Scholar
• JACKSON CE, NORUM RA, BOYD SB et al.: Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome. Surgery (1990) 108(6):1006-1012; discussion 1012-1003.
   PubMed Web of Science ®Google Scholar
• TEH BT, FARNEBO F, KRISTOFFERSSON U et al.: Autosomal dominant primary hyperparathyroidism and jaw tumor syndrome associated with renal hamartomas and cystic kidney disease: linkage to 1q21-q32 and loss of the wild type allele in renal hamartomas. J. Clin. Endocrinol. Metab. (1996) 81(12):4204-4211.
   PubMed Web of Science ®Google Scholar
• BRADLEY KJ, HOBBS MR, BULEY ID et al.: Uterine tumours are a phenotypic manifestation of the hyperparathyroidism-jaw tumour syndrome. J. Intern. Med. (2005) 257(1):18-26.
   PubMed Web of Science ®Google Scholar
• SOOD R, BONNER TI, MAKALOWSKA I et al.: Cloning and characterisation of 13 novel transcripts and the human RGS8 gene from the 1q25 region encompassing the hereditary prostate cancer (HPC1) locus. Genomics (2001) 73:211-222.
   PubMed Web of Science ®Google Scholar
• CARPTEN JD, ROBBINS CM, VILLABLANCA A et al.: HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat. Genet. (2002) 32:676-680.
   PubMed Web of Science ®Google Scholar
• TOMLINSON IP, ROYLANCE R, HOULSTON RS: Two hits revisted again. J. Med. Genet. (2001) 38:81-85.
   PubMed Web of Science ®Google Scholar
• WASSIF WS, FARNEBO F, TEH BT et al.: Genetic studies of a family with hereditary hyperparathyroidism-jaw tumour syndrome. Clin. Endocrinol. (Oxford) (1999) 50(2):191-196.
   PubMed Web of Science ®Google Scholar
• HOWELL VM, HAVEN CJ, KAHNOSKI K et al.: HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J. Med. Genet. (2003) 40(9):657-663.
   PubMed Web of Science ®Google Scholar
• BRADLEY KJ, CAVACO BM, BOWL MR et al.: Parafibromin mutations in hereditary hyperparathyroidism syndromes and parathyroid tumours. Clin. Endocrinol. (Oxford) (2006) 64(3):299-306.
   PubMed Web of Science ®Google Scholar
• CETANI F, PARDI E, AMBROGINI E et al.: Different somatic alterations of the HRPT2 gene in a patient with recurrent sporadic primary hyperparathyroidism carrying an HRPT2 germline mutation. Endocr. Relat. Cancer (2007) 14(2):493-499.
   PubMed Web of Science ®Google Scholar
• WOODARD GE, LIN L, ZHANG JH et al.: Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression. Oncogene (2005) 24(7):1272-1276.
   PubMed Web of Science ®Google Scholar
• ZHANG C, KONG D, TAN MH et al.: Parafibromin inhibits cancer cell growth and causes G1 phase arrest. Biochem. Biophys. Res. Commun. (2006) 350(1):17-24.
   PubMed Web of Science ®Google Scholar
• LIN L, CZAPIGA M, NINI L, ZHANG JH, SIMONDS WF: Nuclear localization of the parafibromin tumor suppressor protein implicated in the hyperparathyroidism-jaw tumor syndrome enhances its proapoptotic function. Mol. Cancer Res. (2007) 5(2):183-193.
   PubMed Web of Science ®Google Scholar
• HAHN MA, MARSH DJ: Identification of a functional bipartite nuclear localization signal in the tumor suppressor parafibromin. Oncogene (2005) 24(41):6241-6248.
   PubMed Web of Science ®Google Scholar
• BRADLEY KJ, BOWL MR, WILLIAMS SE et al.: Parafibromin is a nuclear protein with a functional monopartite nuclear localization signal. Oncogene (2007) 26(8):1213-1221.
   PubMed Web of Science ®Google Scholar
• YART A, GSTAIGER M, WIRBELAUER C et al.: The HRPT2 tumor suppressor gene product parafibromin associates with human PAF1 and RNA polymerase II. Mol. Cell Biol. (2005) 25(12):5052-5060.
   PubMed Web of Science ®Google Scholar
• ROZENBLATT-ROZEN O, HUGHES CM, NANNEPAGA SJ et al.: The parafibromin tumour suppressor protein is part of a human Paf1 complex. Mol. Cell. Biol. (2005) 25(2):612-620.
   PubMed Web of Science ®Google Scholar
• SHI X, CHANG M, WOLF AJ et al.: Cdc73p and Paf1p are found in a novel RNA polymerase II-containing complex distinct from the Srbp-containing holoenzyme. Mol. Cell. Biol. (1997) 17(3):1160-1169.
   PubMed Web of Science ®Google Scholar
• RONDON AG, GALLARDO M, GARCIA-RUBIO M, AGUILERA A: Molecular evidence indicating that the yeast PAF complex is required for transcription elongation. EMBO Rep. (2004) 5(1):47-53.
   PubMed Web of Science ®Google Scholar
• SQUAZZO SL, COSTA PJ, LINDSTROM DL et al.: The Paf1 complex physically and functionally associates with transcription elongation factors in vivo. EMBO J. (2002) 21(7):1764-1774.
   PubMed Web of Science ®Google Scholar
• MUELLER CL, PORTER SE, HOFFMAN MG, JAEHNING JA: The Paf1 complex has functions independent of actively transcribing RNA polymerase II. Mol. Cell (2004) 14(4):447-456.
   PubMed Web of Science ®Google Scholar
• NG HH, DOLE S, STRUHL K: The Rtf1 component of the Paf1 transcriptional elongation complex is required for ubiquitination of histone H2B. J. Biol. Chem. (2003) 278(36):33625-33628.
   PubMed Web of Science ®Google Scholar
• WOOD A, SCHNEIDER J, DOVER J, JOHNSTON M, SHILATIFARD A: The Paf1 complex is essential for histone monoubiquitination by the Rad6-Bre1 complex, which signals for histone methylation by COMPASS and Dot1p. J. Biol. Chem. (2003) 278(37):34739-34742.
   PubMed Web of Science ®Google Scholar
• BETZ JL, CHANG M, WASHBURN TM et al.: Phenotypic analysis of Paf1/RNA polymerase II complex mutations reveals connections to cell cycle regulation, protein synthesis, and lipid and nucleic acid metabolism. Mol. Genet. Genomics (2002) 268:272-285.
   PubMed Web of Science ®Google Scholar
• PORTER SE, WASBURN TM, CHANG M, JAEHNING JA: The yeast Paf1-RNA polymerase II complex is required for full expression of a subset of cell cycle-regulated genes. Eukaryotic Cell (2002) 1(5):830-842.
   PubMed Web of Science ®Google Scholar
• MOSIMANN C, HAUSMANN G, BASLER K: Parafibromin/hyrax activates Wnt/Wg target gene transcription by direct association with β-catenin/armadillo. Cell (2006) 125(2):327-341.
   PubMed Web of Science ®Google Scholar
• BONDESON L, GRIMELIUS L, DELELLIS RA et al.: Parathyroid carcinoma. In: World Health Organisation Classification of Tumours, Pathology and Genetics: Tumour of Endocrine Organs. Delellis RA, Lloyd R, Heitz PU et al. (Eds), IARC Press, Lyon, France (2004):124-127.
   Google Scholar
• SANDELIN K, TULLGREN O, FARNEBO LO: Clinical course of metastatic parathyroid cancer. World J. Surg. (1994) 18(4):594-598; discussion 599.
   PubMed Web of Science ®Google Scholar
• IPPOLITO G, PALAZZO FF, SEBAG F, DE MICCO C, HENRY JF: Intraoperative diagnosis and treatment of parathyroid cancer and atypical parathyroid adenoma. Br. J. Surg. (2007) 94(5):566-570.
   PubMed Web of Science ®Google Scholar
• CETANI F, PARDI E, BORSARI S et al.: Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J. Clin. Endocrinol. Metab. (2004) 89(11):5583-5591.
   PubMed Web of Science ®Google Scholar
• SHATTUCK TM, VALIMAKI S, OBARA T et al.: Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N. Engl. J. Med. (2003) 349(18):1722-1729.
   PubMed Web of Science ®Google Scholar
• KREBS LJ, SHATTUCK TM, ARNOLD A: HRPT2 mutational analysis of typical sporadic parathyroid adenomas. J. Clin. Endocrinol. Metab. (2005) 90(9):5015-5017.
   PubMed Web of Science ®Google Scholar
• MIZUSAWA N, UCHINO S, IWATA T et al.: Genetic analyses in patients with familial isolated hyperparathyroidism and hyperparathyroidism-jaw tumour syndrome. Clin. Endocrinol. (Oxford) (2006) 65(1):9-16.
   PubMed Web of Science ®Google Scholar
• SIMONDS WF, ROBBINS CM, AGARWAL SK et al.: Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. J. Clin. Endocrinol. Metab. (2004) 89(1):96-102.
   PubMed Web of Science ®Google Scholar
• WARNER J, EPSTEIN M, SWEET A et al.: Genetic testing in familial isolated hyperparathyroidism: unexpected results and their implications. J. Med. Genet. (2004) 41(3):155-160.
   PubMed Web of Science ®Google Scholar
• CAVACO BM, GUERRA L, BRADLEY KJ et al.: Hyperparathyroidism-jaw tumor syndrome in Roma families from Portugal is due to a founder mutation of the HRPT2 gene. J. Clin. Endocrinol. Metab. (2004) 89(4):1747-1752.
   PubMed Web of Science ®Google Scholar
• ZHAO J, YART A, FRIGERIO S et al.: Sporadic human renal tumors display frequent allelic imbalances and novel mutations of the HRPT2 gene. Oncogene (2007) 26(23):3440-3449.
   PubMed Web of Science ®Google Scholar
• PIMENTA FJ, GONTIJO SILVEIRA LF, TAVARES GC et al.: HRPT2 gene alterations in ossifying fibroma of the jaws. Oral Oncol. (2006) 42(7):735-739.
   PubMed Web of Science ®Google Scholar
• ALDRED MJ, TALACKO AA, SAVARIRAYAN R et al.: Dental findings in a family with hyperparathyroidism-jaw tumor syndrome and a novel HRPT2 gene mutation. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. (2006) 101(2):212-218.
   PubMedGoogle Scholar
• HAVEN CJ, HOWELL VM, EILERS PH et al.: Gene expression of parathyroid tumors: molecular subclassification and identification of the potential malignant phenotype. Cancer Res. (2004) 64(20):7405-7411.
   PubMed Web of Science ®Google Scholar
• GILL AJ, CLARKSON A, GIMM O et al.: Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am. J. Surg. Pathol. (2006) 30(9):1140-1149.
   PubMed Web of Science ®Google Scholar
• CETANI F, AMBROGINI E, VIACAVA P et al.: Should parafibromin staining replace HRPT2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? Eur. J. Endocrinol. (2007) 156(5):547-554.
   PubMed Web of Science ®Google Scholar
• TAN MH, MORRISON C, WANG P et al.: Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin. Cancer Res. (2004) 10(19):6629-6637.
   PubMed Web of Science ®Google Scholar
• JUHLIN CC, VILLABLANCA A, SANDELIN K et al.: Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification. Endocr. Relat. Cancer (2007) 14(2):501-512.
   PubMed Web of Science ®Google Scholar
• BRADLEY KJ, CAVACO BM, BOWL MR et al.: Utilisation of a cryptic non-canonical donor splice site of the gene encoding PARAFIBROMIN is associated with familial isolated primary hyperparathyroidism. J. Med. Genet. (2005) 42(8):E51.
   PubMedGoogle Scholar
• GUARNIERI V, SCILLITANI A, MUSCARELLA LA et al.: Diagnosis of parathyroid tumors in familial isolated hyperparathyroidism with HRPT2 mutation: implications for cancer surveillance. J. Clin. Endocrinol. Metab. (2006) 91(8):2827-2832.
   PubMed Web of Science ®Google Scholar
• VILLABLANCA A, CALENDER A, FORSBERG L et al.: Germline and de novo mutations in the HRPT2 tumour suppressor gene in familial isolated hyperparathyroidism (FIHP). J. Med. Genet. (2004) 41(3):E32.
   PubMed Web of Science ®Google Scholar
• WARNER JV, NYHOLT DR, BUSFIELD F et al.: Familial isolated hyperparathyroidism is linked to a 1.7 Mb region on chromosome 2p13.3-14. J. Med. Genet. (2006) 43(3):E12.
   PubMed Web of Science ®Google Scholar
• JUHLIN C, LARSSON C, YAKOLEVA T et al.: Loss of parafibromin expression in a subset of parathyroid adenomas. Endocr. Relat. Cancer (2006) 13(2):509-523.
   PubMed Web of Science ®Google Scholar
• MOON S, PARK J, KIM E et al.: A novel IVS2-1G>A mutation causes aberrant splicing of the HRPT2 gene in a family with hyperparathyroidism-jaw tumour syndrome. J. Clin. Endocrinol. Metab. (2005) 90(2):878-883.
   PubMed Web of Science ®Google Scholar